Daewoong Pharmaceutical successfully held ‘NABOTA SEOUL 2018’

Daewoong Pharmaceutical successfully held ‘NABOTA SEOUL 2018’ -      Presented result of Nabota clinical study and latest trend of US botulinum toxin -      Over 200 plastic surgeons attended from Korea, US, UAE, Thailand, Vietnam, and Philippines On Jul. 6, Daewoong Pharmaceutical (CEO Sengho Jeon) announced that NABOTA SEOUL 2018 held on Jul. 5 in Intercontinental Seoul COEX Hotel was a success. The symposium was to commemorate FDA cGMP and EU CMP approval for the manufacturing facility for Nabota and was attended by over 200 plastic surgeons from Korea, US, UAE, Thailand, Vietnam and Philippines. September Riharb, vice president of marketing, and Dr. Rui Avelar, chief medical officer, at Evolus, Daewoong’s partner in the US, and Dr. Kristine Romine, a US dermatologist, also attended the event as speakers. After the opening address by Daewoong Pharmaceutical CEO Sengho Jeon, the event was followed by introduction of Evolus and expectation and competitiveness of Nabota(DWP-450) in the US market by September Riharb and results of phase 2 and 3 clinical studies in the US and Europe by Dr. Rui Avelar. Dr. Kristine Romine presented on US botulinum toxin market and regimen. Dr. Avelar said, “Nabota(DWP-450) proved its non-inferiority compared to Botox in various clinical studies conducted in Korea, US, Canada and Europe. Based on statistical data from the studies, Nabota actually was better than Botox. In a phase 3 clinical trial conducted in the US on 654 subjects, on the 30th day, of the 4-stage wrinkle scales, both researchers and subjects had improved wrinkles of over 2 stages, at the same time. The ratio reached almost 70%, substantiating its efficacy even in clinical trials with heightened difficulty,” stressing the efficacy and safety of Nabota. She also said, “We are very excited about the launch of 900KDa, the first ever to be launched after Botox in the US. Evolus’ abundant experience in the aesthetics market and Daewoong Pharmaceutical’s outstanding manufacturing technology and facilities will make Nabota the fastest growing botulinum toxin product in the global market.” Daewoong Pharmaceutical CEO Sengho Jeon stated, “At the symposium, we were able to inform everyone on the performance of Nabota and our advanced production facilities and products. We will continue to work with Evolus and make Nabota a global botulinum toxin brand.” #  #  # [Photo] ‘NABOTA SEOUL 2018’ [Photo 1] Dr. Rui Avelar, Chief Medical Officer, Evolus, presenting result of Nabota clinical trial [Photo 2] (From left) Dr. Hasan Galadari, UAE dermatologist, September Ribarb, vice president of marketing of Evolus, Sengho Jeon, CEO of Daewoong Pharmaceuticlas, Jennifer Harris, marketing director of Evolus, Dr. Rui Avelar, Chief Medical Officer of Evolus, Dr. Kristine Romine and Dr. Mary Lupo, dermatologists, Dr. Holly Wall and Dr. Simion Wall, US plastic surgeons, Yungyeong Cha, Nabota Business Team Leader, and Seongsu Park, head of Nabota Business HQ

The release as fetched from its publisher. daewoong.co.kr ↗